Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Derwent London reports strong H1 leasing activity, rising rental values

(Sharecast News) - Property investor and developer Derwent London said on Tuesday that it had seen strong leasing activity and rising rental values throughout H1. Derwent London said demand for its high-quality office spaces in central London had remained well above the long-term average, with supply constraints supporting pricing power.

Gross rental income ticked up 1.5% year-on-year to £109.1m, while net rental income dipped 1.1% to £94.0m. EPRA earnings per share slipped 0.9% to 52.2p, though IFRS pre-tax profits rebounded to £94.0m from a £27.2m loss a year earlier.

Net debt rose 4.7% to £1.55bn, with EPRA loan-to-value increasing to 30.5% from 29.9%, while interest cover fell to 3.2x from 3.9x, and net debt to EBITDA climbed to 9.7x.

However, the group reported £604m in cash and undrawn facilities, up from £487m at year-end, and lifted its interim dividend by 2.0% to 25.5p.

Open-market lettings were agreed 10.5% ahead of estimated rental values, with £13.8m of leasing, renewals, and regears completed year-to-date. Underlying capital growth turned positive at 1.2%, while total return improved to 3.0% from -1.0%.

Looking forward, Derwent London reiterated rental growth guidance of 3-6% for FY25 and confirmed over £200m of disposals had been completed or contracted, with proceeds earmarked for developments including Holden House and 50 Baker Street.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.